PI
PIQ.AU Proteomics International Laboratories Ltd
- Market cap
- AUD 19.8M
- P/E
- -
- P/B
- 3.42x
- ROE
- -147.4%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PIQ.AU undervalued?
Graham numberThe Graham number of Proteomics International Laboratories Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Proteomics International Laboratories Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-147.4%), below 10%.
ROA 0/1
Return on assets (-96.4%) is below the industry median (-36.5%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (4.0%) is below the industry median (12.5%).
Revenue Growth 0/2
Revenue shrank 27.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (5.7%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.4x) is above the industry median (3.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Proteomics International Laboratories Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validat…
Full company profileProteomics International Laboratories Ltd financial statements
Proteomics International Laboratories Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 925K | 1.18M | 1.47M | 1.42M | 1.31M | 1.49M | 730K | 892K | 960K | 278K |
| Gross Profit | -1.35M | -1.33M | 1.38M | 585K | 497K | -569K | -1.62M | -1.12M | 960K | -9.07M |
| Operating Income | 7.39M | -2.35M | -1.85M | -2.00M | -3.08M | -4.98M | -6.37M | -9.12M | -10.6M | -11.9M |
| EBITDA | -694K | -1.16M | -1.66M | -1.70M | -2.77M | -4.56M | -7.55M | -8.40M | -10.00M | -11.1M |
| Net Income | -916K | -1.44M | -2.08M | -1.74M | -2.86M | -4.97M | -6.23M | -6.38M | -8.11M | -8.56M |
| EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 2.89M | 5.49M | 3.62M | 5.55M | 8.60M | 5.40M | 10.1M | 10.9M | 14.8M | 8.88M |
| Total Liabilities | 1.28M | 818K | 635K | 1.12M | 990K | 2.00M | 1.75M | 1.63M | 1.81M | 3.33M |
| Shareholders' Equity | 1.61M | 4.68M | 2.99M | 4.44M | 7.61M | 3.39M | 8.38M | 9.41M | 13.2M | 5.81M |
| Cash & Short-term Investments | 775K | 2.32M | 1.51M | 2.37M | 5.60M | 2.11M | 6.03M | 6.64M | 11.0M | 3.50M |
| Total Debt | 875K | 312K | 165K | 133K | 69.0K | 356K | 64.1K | 316K | 278K | 331K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.47M | -1.08M | -1.67M | -385K | -2.21M | -3.54M | -5.69M | -5.59M | -6.60M | -5.87M |
| Capital Expenditure | 147K | 50.5K | 38.0K | 1.59M | 205K | 129K | 1.22M | 403K | 29.6K | 2.01M |
| Free Cash Flow | -1.62M | -1.13M | -1.71M | -1.97M | -2.41M | -3.67M | -6.91M | -6.00M | -6.63M | -7.88M |
| Ratios | ||||||||||
| ROE | -56.9% | -30.8% | -69.7% | -39.3% | -37.6% | -146.5% | -74.4% | -67.7% | -61.6% | -147.4% |
| ROA | -31.7% | -26.2% | -57.5% | -31.4% | -33.3% | -92.2% | -61.9% | -58.6% | -54.9% | -96.4% |
| Net Profit Margin | -99.0% | -122.4% | -141.7% | -122.5% | -218.2% | -333.9% | -853.6% | -714.7% | -844.9% | -3,078.9% |
| Debt to Equity | 0.54x | 0.07x | 0.06x | 0.03x | 0.01x | 0.10x | 0.01x | 0.03x | 0.02x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Proteomics International Laboratories Ltd dividends
Proteomics International Laboratories Ltd has not paid dividends in the last 10 fiscal years.
Who owns Proteomics International Laboratories Ltd
- Insiders 26.69%
- Institutions 7.02%
- Public & others 66.30%
- Shares outstanding 165M
- Free float 128M
Proteomics International Laboratories Ltd company profile
- Company name
- Proteomics International Laboratories Ltd
- Ticker
- PIQ.AU
- ISIN
- AU000000PIQ0
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- June
- Address
- Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009
- Phone
- 61 8 9389 1992
- Website
- proteomics.com.au
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.
Proteomics International Laboratories Ltd management
5- Mr. David N. Morris BAppSc, BBusMD, CEO & Director
- Mr. Timothy Luscombe B.Com., C.A.CFO & Company Secretary
- Dr. Scott Bringans Ph.D.Chief Scientific Officer
- Mr. Phillip Prather B.Sc.Chief Commercial Officer
- Dr. Kirsten PetersDirector of Clinical Science